Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin for Hyperphosphatemia in ESRD
NCT03163576Phase 4
Key facts
- Status
- Unknown
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Sponsor
- Assiut University
- Modality
- Small Molecules
- Drugs
- niacin
- Conditions
- hyperphosphatemia
01
Overview
Phase 4, randomised trial of niacin in hyperphosphatemia (2 arms), sponsored by Assiut University. Primary endpoint: Serum phosphorus level at 2 years. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Study Group
Niacin 750-2000 mg bid + Phosphate Binders
Control Group
Usual Phosphate Binders
03
Endpoints
Primary
Serum phosphorus level
Beyond the preview
Go deeper on NCT03163576.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163576.